The future of personalized medicine hinges on developing high-resolution, home-based biosensors that provide the continuous, high-fidelity data needed to power foundational AI models. In this episode, Rich Yang, CEO of Biolinq, shares his 27-year journey in diabetes and biosensing, beginning with the first FDA-approved CGM and leading to his current role. He describes the ambitious goal of building a novel semiconductor biosensor that combines five complex disciplines: semiconductor manufacturing, software, material science, consumer electronics, and scaling. Rich highlights Biolinq’s unique value proposition, which includes metabolic tracking, real-time LED feedback, and multi-electrode reliability. He also reflects on the future of multi-analyte sensing, the importance of hiring resilient talent, and how deep tech is shaping proactive health management. Tune in and learn how deep tech is revolutionizing metabolic health and what it takes to lead a team through unprecedented technological hurdles! Resources: Connect with and follow Rich Yang on LinkedIn. Follow Biolinq on their LinkedIn and visit their website.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related